Sectors
JBIO
Jade Biosciences, Inc.
21.36
1 x 20.61
1 x 20.86
bid
ask
+
0.52
2.50%
1 @ 07:30 PM
21.36 +0.00 (0.00%)
| Ytd | 38.43% | |
| 1y | 170.38% |
20.35
day range
21.45
6.91
52 week range
28.00
| Open | 20.65 | Prev Close | 20.84 | Low | 20.35 | High | 21.45 | Mkt Cap | 1.36B |
| Vol | 837.04K | Avg Vol | 1.12M | EPS | -1.07 | P/E | N/A | Forward P/E | -8.02 |
| Beta | 1.49 | Short Ratio | 11.10 | Inst. Own | 115.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 21.33 | 200-d Avg | 17.76 | 1yr Est | 50.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.73 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.64 | -0.76 | -0.12 | -19.42% |
| 2026-05-07 | 2026-03 | -0.52 | -0.57 | -0.05 | -9.62% |
| 2026-03-06 | 2025-12 | -0.45 | -0.45 | N/A | N/A |
| 2025-11-14 | 2025-09 | -0.57 | -0.48 | 0.09 | 15.79% |
| 2025-08-14 | 2025-06 | -0.43 | -0.86 | -0.43 | -100.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-11 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-10 | BTIG | Upgrade | Buy | Buy |
| 2026-06-15 | UBS | Upgrade | Buy | |
| 2026-06-02 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-01 | BTIG | Upgrade | Buy | Buy |
| 2026-06-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-11 | BALTA ELIZABETH | Officer | 28.13K | Stock Award(Grant) |
| 2026-02-11 | DAHMS BRADFORD D | Chief Financial Officer | 37.81K | Stock Award(Grant) |
| 2025-10-05 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2026-02-11 | FROHLICH TOM | Chief Executive Officer | 86.33K | Stock Award(Grant) |
| 2026-02-11 | KING ANDREW JAMES | Officer | 386.11K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 9.13M | 194.95M | 14.35% |
| 2026-06-29 | Jupiter Topco LLC | 6.27M | 134.00M | 9.86% |
| 2026-06-29 | Fairmount Funds Management LLC | 4.55M | 97.26M | 7.16% |
| 2026-06-29 | RA Capital Management, L.P. | 3.67M | 78.41M | 5.77% |
| 2026-06-29 | Venrock Adviser, LLC | 3.22M | 68.79M | 5.06% |
| 2026-06-29 | Bellevue Group AG | 3.06M | 65.32M | 4.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.53M | 32.64M | 2.40% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.39M | 29.59M | 2.18% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.19M | 25.46M | 1.87% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 852.07K | 18.20M | 1.34% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 819.58K | 17.51M | 1.29% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 716.80K | 15.31M | 1.13% |
Dividend
| Dividend | Date |
|---|---|
| 2.4 | 2025-04-29 |